ArticleJournal of behavioral medicine2020
Assessing gender identity differences in cardiovascular disease in US adults: an analysis of data from the 2014-2017 BRFSS.
Article in Journal of behavioral medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Determinants of Cardiovascular Disease Risk Among LGBTQ+ Populations: A Systematic Review of Empirical Evidence.Nursing open · 2026Pooled it
- Effects of a group-based compassion microintervention compared to cognitive reappraisal training on cardiovascular, self-reported, and behavioral stress reactivity among young adults: A cluster randomized controlled trial.Applied psychology. Health and well-being · 2025Trial
- Nationwide estimates of all-cause and cause-specific mortality among individuals with gender dysphoria in Sweden, 2001-2023: a register-based cohort study.EClinicalMedicine · 2026Article
- Visceral adipose tissue and liver fat on 17-beta estradiol-dominant gender-affirming hormone therapy: A US-based cohort.The Journal of clinical endocrinology and metabolism · 2026Observational
- Sexual orientation, gender identity and cardiometabolic risk: a narrative review.Diabetologia · 2025Review
- Cardiovascular risk of gender-affirming estrogen therapy in a transgender rat model.Journal of molecular medicine (Berlin, Germany) · 2025Article
- Echoes of Inequity: A Critical Examination of the Past, Present, and Future of Cardiac Health Equity.Current cardiology reports · 2025Review
- Hormone Replacement Therapy and Cardiovascular Health in Postmenopausal Women.International journal of molecular sciences · 2025Review
- Sex differences in associations of metabolic inflammation and insulin resistance with incident type 2 diabetes mellitus: a retrospective cohort of adults with annual health examinations.Lipids in health and disease · 2025Article
- Gender-affirming hormone therapy: effects on cardiovascular risk and vascular function.Endocrine connections · 2025Article
- Relation Between the Negative Cognitive Triad, Perceived Everyday Discrimination, Depressive Symptoms, and TNF-⍺ in Adolescents.Child psychiatry and human development · 2024Article
- Transgender Women With Suppressed Testosterone Display Lower Burden of Coronary Disease Than Matched Cisgender Men.Journal of the Endocrine Society · 2024Article
- Review
- Approach to the Patient: Hormonal Therapy in Transgender Adults With Complex Medical Histories.The Journal of clinical endocrinology and metabolism · 2024Article
- The impact of gender-affirming hormone therapy on nutrition-relevant biochemical measures.Frontiers in nutrition · 2024Review
- Thromboembolic risk with gender-affirming hormone therapy: potential role of global coagulation and fibrinolysis assays.Research and practice in thrombosis and haemostasis · 2023Review
- Obesity in Sexual and Gender Minority Populations: Prevalence and Correlates.Current obesity reports · 2023Review
- Disparities in health condition diagnoses among aging transgender and cisgender medicare beneficiaries, 2008-2017.Frontiers in endocrinology · 2023Article
- Gender-affirming hormone therapy, mental health, and surgical considerations for aging transgender and gender diverse adults.Therapeutic advances in endocrinology and metabolism · 2023Review
- Cardiovascular disease risk in the transgender population.Archivos de cardiologia de Mexico · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The purpose of this study was to assess gender identity differences in CVD risk and CVD conditions among adults in the U.S. Using data from the 2014-2017 BRFSS we compared CVD risk and CVD conditions in gender minorities (transgender men, transgender women and gender nonconforming persons) to both cisgender men and women. The sample consisted of 662,903 participants. Transgender women (AOR 1.34, 95% CI 1.05-1.72) and transgender men (AOR 1.54, 95% CI 1.07-2.24) were more likely to be overweight than cisgender women. Compared to cisgender women, transgender women reported higher rates of diabetes (AOR 1.45, 95% CI 1.05-1.99), angina/coronary heart disease (AOR 1.90, 95% CI 1.34-2.68), stroke (AOR 1.88, 95% CI 1.16-3.03), and myocardial infarction (AOR 2.98, 95% CI 2.14-4.17). Gender nonconforming participants (AOR 2.68, 95% CI 1.14-6.30) reported higher odds of myocardial infarction than cisgender women. Transgender women also had higher rates of reporting any CVD than cisgender men (AOR 1.38, 95% CI 1.01-1.88). There is a need to elucidate the cardiovascular effects of minority stressors and gender affirming therapy in this population. More research focused on CVD prevention and management in gender minorities is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.